论文信息 - Which AML subsets benefit from leukemic cell priming during chemotherapy? Long‐term analysis of the ALFA‐9802 GM‐CSF study - 字舞流文

Which AML subsets benefit from leukemic cell priming during chemotherapy? Long‐term analysis of the ALFA‐9802 GM‐CSF study

H. Dombret | C. Preudhomme | C. Gardin | S. de Botton | X. Thomas | S. Hayette | Aline Renneville | C. Terré | E. Raffoux | C. Pautas